|
Jan 3, 2017 |
REDWOOD CITY, Calif., Jan. 3, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits, chairman of the board, chief executive officer and president, will present at the 35th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Monday, January 9, 2017 at 11:00 a.m. Pacific Ti...
|
|
|
Dec 22, 2016 |
REDWOOD CITY, Calif., Dec. 22, 2016 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that based on unparalleled clinical evidence, the American Joint Committee on Cancer (AJCC) incorporated the Oncotype DX® test in its recently published Eighth Edition AJCC Cancer Staging Manual. Representing a rigorous, multi-disciplinary a...
|
|
|
Dec 9, 2016 |
REDWOOD CITY, Calif., Dec. 9, 2016 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced results from multiple studies demonstrating the unparalleled value of the Oncotype DX® test in individualizing breast cancer treatment decisions for patients with various stages of the disease. Presentations included two overviews of prospect...
|
|
|
Nov 29, 2016 |
REDWOOD CITY, Calif., Nov. 29, 2016 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present seven Oncotype DX® studies at the 39th CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), which is being held December 6-10, 2016. The study findings reinforce the Company's leadership in individualizing breast cance...
|
|
|
Nov 3, 2016 |
REDWOOD CITY, Calif., Nov. 3, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole, chief operating officer and chief financial officer, will present at the Credit Suisse 25th Annual Healthcare Conference in Scottsdale, Arizona on Tuesday, November 8, 2016 at 3:30 p.m. Mountain Time.
To access the live and...
|
|
|
Nov 1, 2016 |
REDWOOD CITY, Calif., Nov. 1, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended September 30, 2016.
Total revenue was $82.3 million in the third quarter of 2016, compared with $73.6 million in the third quarter of 2015, an increase of 12 percent.
U.S. ...
|
|
|
Nov 1, 2016 |
REDWOOD CITY, Calif., Nov. 1, 2016 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced topline results from a large clinical validation study of its biopsy-based Oncotype DX® Genomic Prostate Score™ (GPS). The study, performed in collaboration with a large integrated healthcare system, met its primary endpoint by demonstr...
|
|
|
Oct 26, 2016 |
REDWOOD CITY, Calif., Oct. 26, 2016 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced publication in Reviews in Urology of a comprehensive economic analysis of the use of the Oncotype DX® Genomic Prostate ScoreTM (GPS) in low-risk prostate cancer patients. Results showed that use of the GPS results in a net savings of $2,286 ...
|
|
|
Oct 25, 2016 |
REDWOOD CITY, Calif., Oct. 25, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, November 1 at 4:30 p.m. Eastern Time to discuss its third quarter 2016 financial results. The call and webcast will follow the release of the third quarter financial results aft...
|
|
|
Oct 11, 2016 |
REDWOOD CITY, Calif., Oct. 11, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from its successfully completed analytical validation study of Oncotype SEQ™ Liquid Select, which demonstrated that this liquid biopsy mutation panel is highly sensitive, specific and reproducible. To provide transparent and clinica...
|
|
